Under the partnership, Indivumed's IndivuType multiomics cancer database will be paired with genome and transcriptome-level data from thousands of samples using Personalis' cancer genomics technology, according to the firms. Pairing the two platforms will provide innovative solutions for tumor genomics characterization and insights into oncology therapeutics.

Indivumed CEO and Founder Dr. Hartmut Juhl said that adding Personalis' technology to the IndivuType multiomics profile will enable relevant discoveries in the firm's pharma and biotech collaborations and further its mission of advancing precision oncology.